Concise report

Myocardial fibrosis and arrhythmic burden in systemic sclerosis

Laura Ross 1,2, Benedict Costello3,4, Zoe Brown1,2, Dylan Hansen2, Anniina Lindqvist3, Wendy Stevens2, Andrew Burns1,4, David Prior1,4, Mandana Nikpour1,2,* and André La Gerche1,3,4,*

Abstract

Objectives. Cardiac complications of SSc are a leading cause of SSc-associated death. Cardiac imaging for identifying substrate abnormality may be useful in predicting risk of cardiac arrhythmias or future cardiac failure. The aim of this study was to quantify the burden of asymptomatic fibro-inflammatory myocardial disease using cardiac magnetic resonance imaging (CMR) and assess the relationship between asymptomatic myocardial fibrosis and cardiac arrhythmias in SSc.

Methods. Thirty-two patients with SSc with no documented history of pulmonary vascular or heart disease underwent CMR with gadolinium and 24-h ambulatory ECG. Focal myocardial fibrosis was assessed using post-gadolinium imaging and diffuse fibro-inflammatory myocardial disease quantified using T1- and T2-mapping. CMR results were compared with an age- and sex-matched control group.

Results. Post-gadolinium focal fibrosis was prevalent in SSc but not controls (30% vs 0%, p < 0.01). T1-mapping values (as a marker of diffuse fibrosis) were greater in SSc than controls [saturated recovery single-shot acquisition (SASHA): 1584 ms vs 1515 ms, p < 0.001; shortened Modified look locker sequence (ShMOLLI): 1218 ms vs 1138 ms, p < 0.001]. More than one-fifth (22.6%) of the participants had ventricular arrhythmias on ambulatory ECG, but no associations between focal or diffuse myocardial fibrosis and arrhythmias were evident.

Conclusion. In SSc patients without evidence of overt cardiac disease, a high burden of myocardial fibrosis and arrhythmias was identified. However, there was no clear association between focal or diffuse myocardial fibrosis and arrhythmias, suggesting CMR may have limited use as a screening tool to identify SSc patients at risk of future significant arrhythmias.

Key words: SSc (scleroderma), myocardial fibrosis, arrhythmia

Introduction

Cardiopulmonary complications are the leading cause of SSc-associated death [1]. Fibrotic, inflammatory and vasculopathic changes affecting all structures of the heart have been detected in up to 80% of patients at autopsy [2]. However, clinical detection of SSc-associated heart involvement (SHI) remains
challenging as findings can be subtle and non-specific [3].

It is hypothesized that cardiac arrhythmias and conduction defects arise from damaged, fibrotic myocardium [4]. Both patchy and diffuse myocardial fibrosis have been described in SSc [2]. Focal fibrosis may be identified with traditional post-contrast cardiac magnetic resonance (CMR) techniques but the advent of T1-mapping sequences and extra-cellular volume quantification (ECV) now enables the characterization of diffuse fibrosis. Abnormalities of T1-mapping are not specific to a single disease but they are a viable biomarker for quantifying the extent of fibrosis, and may potentially indicate reversible changes that can improve with treatment [5]. It is yet to be established whether asymptomatic diffuse fibro-inflammatory myocardial changes in SSc are associated with arrhythmias and whether they may serve as a potential treatment target to reduce the risk of future arrhythmias. We aimed to characterize the burden of fibro-inflammatory cardiac disease in SSc and to evaluate whether fibrotic myocardial disease was associated with arrhythmias.

**Methods**

Adult patients (age >18 years) with SSc who fulfilled the 2013 ACR/EULAR SSc classification criteria [6] were invited to participate if they had no history of myocarditis, ischaemic heart disease (based on clinical history and absence of any symptoms), pulmonary arterial hypertension (PAH) diagnosed by right heart catheterization, renal impairment (estimated glomerular filtration rate <40 mL/min/1.73 m²), current atrial fibrillation or moderate to severe valvular disease. Patients were deliberately recruited across the spectrum of SSc disease and were eligible for inclusion if they had a disease duration <4 years or >10 years in order to ensure patients with both early and long-standing disease were recruited. Onset of disease was dated from the first presentation of a non-Raynaud’s disease manifestation. All patients were classified according to LeRoy criteria as either lcSSc or dcSSc [7].

Study participants underwent a clinical evaluation and cardiac investigation with CMR and 24-h ambulatory ECG monitoring. CMR data were compared with a group of age- and sex-matched individuals with no history of cardiac disease. All CMR examinations were performed on a 3 T scanner (Magnetom Prisma, Siemens Healthineers, Erlangen, Germany). Patients underwent native T1- and T2-mapping to measure diffuse fibrotic and inflammatory myocardial changes, respectively. Post-contrast imaging was obtained after administration of gadolinium enhancement to visualize any focal fibrotic myocardial changes. CMR was performed and images evaluated according to validated local institutional protocols [8] by two authors (B.C., A.L.G.) blinded to clinical data. A detailed description of the CMR protocol can be found in the Supplementary Materials, available at Rheumatology online.

**Ambulatory electrocardiography**

All patients underwent ambulatory ECG monitoring with a 3-lead, 24-h Holter monitor (PocketECG, Medical gorithmics S.A., Warsaw, Poland). Complete traces were assessed for the presence of atrial and ventricular arrhythmias. The number of atrial and ventricular ectopic beats was recorded. Ventricular arrhythmias of interest were ventricular couplets or triplets, ventricular bigeminy, ventricular trigeminy and ventricular tachycardia. Ambulatory ECG data were analysed by one investigator (A.L.G.), blinded to clinical and CMR data.
All patients gave written informed consent to participate in the study. Ethics approval was granted by St Vincent’s Hospital, Melbourne Human Research Ethics Committee (HREC181/18) and the study was performed in accordance with the Declaration of Helsinki. Study data were collected and managed using the REDCap electronic data capture tool hosted at The University of Melbourne.

**Statistical analyses**

Continuous variables are presented as mean (s.d.) or median (inter quartile range). Categorical variables are presented as number (percentage). The paired sample t test or the Wilcoxon matched-pairs sign-rank test was used to compare continuous variables, as appropriate. The χ² test was used to compare dichotomous data. The relationship between rhythm abnormalities and myocardial fibrosis was evaluated using linear regression analysis for continuous outcome variables and logistic regression analysis for categorical outcome variables. A p-value of ≤ 0.05 was considered statistically significant. Statistical analysis was performed using STATA 15.1 (StataCorp, College Station, TX, USA).

**Results**

**Patient demographics**

Thirty-four patients were recruited to the study. Thirty-one scans were available for analysis. One patient was unable to tolerate CMR due to claustrophobia and another patient was lost to follow-up prior to cardiac investigations being performed. Images from one CMR were not interpretable due to a high burden of ventricular ectopic beats (VEs). One patient did not receive gadolinium contrast. Baseline characteristics of the study population are presented in Table 1.

**Cardiac magnetic resonance imaging findings**

SSc patients had a significantly higher LVEF compared with controls (64.38% vs 61.09%, p = 0.035) but decreased global longitudinal strain (~16.68% vs ~20.30%, p < 0.001). SSc patients had increased myocardial fibrosis indicated by elevated native T1-times. Twenty-nine (93.5%) patients recorded a native T1-time above the upper limit of normal. Nine patients (30%) had focal regions of late gadolinium enhancement (LGE) detected. SSc patients had increased myocardial oedema measured by T2-mapping time (42.20 vs 36.26 ms, p < 0.001) (see Supplementary Materials, available at Rheumatology online). No SSc disease features were significantly associated with diffuse fibro-inflammatory myocardial disease, including disease duration and extent of cutaneous involvement.

**Ambulatory electrocardiography findings**

The 24-h ambulatory ECG findings are summarized in Table 1. One patient recorded an episode of non-sustained ventricular tachycardia (VT) of 4 beats at a rate of 128 beats per min. Asymptomatic paroxysmal atrial fibrillation was detected in one patient, who recorded a 5-h period of rate-controlled atrial fibrillation. There was no association between myocardial fibrosis, measured by native T1 or LGE and the presence of atrial or ventricular ectopy (see Table 2). The one patient who recorded a run of non-sustained VT had no LGE detected on CMR. Ventricular arrhythmias (couplet, triplet, bigeminy, trigeminy, VT) were not associated with either elevated T1-mapping or T2-mapping times or the presence of LGE.

**Discussion**

In a study of patients with SSc and no clinical evidence of cardiac disease we found that both myocardial fibro-inflammation on CMR and arrhythmias were highly prevalent. However, there was no clear association between these two abnormalities.

Diffuse myocardial fibrosis was clearly present, as evidenced by differences in the group means for T1-mapping values and the fact that almost every patient with SSc had values above established normal reference values [8]. Unexpectedly, we detected pathological myocardial fibrosis in patients early in their disease course with limited skin involvement and no significant internal organ involvement, a patient group generally expected to have a more benign disease course. Our results show that there are no reliable clinical indicators to predict which patients are at higher risk of diffuse myocardial fibrosis.

Our results concur with previous studies that have shown diffuse myocardial fibrosis is a characteristic hallmark of SSc [9–15]. However, the exact prognostic implications of myocardial fibrosis in the absence of cardiac symptoms remain unclear. The characteristic fibrosis associated with SSc is known to involve the myocardium with the potential to manifest as arrhythmias or sudden death. In other cardiomyopathies, myocardial fibrosis serves as a potential substrate for arrhythmias [16] and ventricular ectopy in structurally abnormal hearts is linked to an increased risk of death [17]. Higher ECV has been associated with an increased risk of major cardiovascular events and mortality in non-ischaemic cardiomyopathy, valvular heart disease and amyloidosis [16].

Although we did not find an association between greater ECV and arrhythmias, a potential for clinical events resulting from diffuse myocardial disease in SSc remains. Prior studies have evaluated the potential link between myocardial fibrosis and arrhythmias. A recent study that included participants with cardiac symptoms or events proposed that a combination of myocardial oedema measured by T2 ratio and percentage burden of LGE could be used to predict the development of rhythm disturbances [18]. A prospective study that included evaluation with T1-mapping sequences demonstrated an increased risk of cardiac events, including rhythm disturbances, in patients with high native T1-times [15]. However, this study included patients with PAH, a history of renal crisis and ischaemic heart...
disease, all of which may potentially confound results. It has been hypothesized that myocardial fibrosis in SSc accrues as a result of microcirculatory dysfunction, a so-called ‘cardiac RP’ [19]. Myocardial microvascular dysfunction, particularly in those patients with other vascular manifestations such as PAH or renal crisis, may in part explain the burden of diffuse fibrosis observed in these patients.

This study deliberately selected participants to exclude important cardiovascular comorbidities such as PAH and ischaemic heart disease that commonly confound cardiac assessment of SSc patients. Our observed absence of an association between fibrosis and arrhythmias is consistent with a study by Bissell et al. which assessed patients with no ostensible cardiovascular disease using an implantable loop recorder over 3 years. They observed a high prevalence of arrhythmias but no significant association with CMR parameters of fibrosis [20]. It is likely the prognostic significance of CMR evidence of myocardial fibrosis needs to be considered in light of the presence of cardiac symptoms and its potential utility in the prediction of poor outcomes is in those patients who report cardiac symptoms.

| Demographics | n = 31 |
|--------------|-------|
| Age, mean (s.d.), years | 55.10 (7.54) |
| Female, n (%) | 23 (74) |
| Disease duration, mean (s.d.), years | 9.71 (7.33) |
| Disease onset < 4 years, n (%) | 12 (39) |
| lcSSc/dcSSc, n (%) | 13 (42)/18 (58) |
| Antibodies, n (%) | |
| Centromere | 8 (26) |
| Scl-70 | 12 (39) |
| RNA polymerase III | 3 (10) |
| Cardiac biomarkers, median (IQR) | |
| Troponin | 4 (2, 8) |
| BNP | 31 (13, 52) |
| Current smokers, n (%) | 2 (6) |
| BMI (kg/m²), mean (s.d.) | 25.00 (4.57) |
| Hypertension, n (%) | 2 (6) |
| Diabetes mellitus, n (%) | 1 (3) |
| SSc disease manifestations | |
| Raynaud phenomenon, n (%) | 31 (100) |
| Digital ulcers, n (%) | 16 (52) |
| mRSS, median (IQR) | 10 (3, 17) |
| Interstitial lung diseasea, n (%) | 10 (32) |
| FVC (% predicted), mean (s.d.) | 88.03 (20.53) |
| Inflammatory arthritis, n (%) | 19 (61) |
| Myositis, n (%) | 2 (6) |
| Electrocardiography results | |
| Average heart rate, mean (s.d.) | 79 (8) |
| Significant heart block or sinus pause > 2 s, n (%) | 0 (0) |
| Atrial ectopic beats, n (%) | 28 (90.32) |
| Number of atrial ectopic beats, mean (s.d.) | 1430 (6185) |
| > 50 atrial ectopic beats, n (%) | 14 (45) |
| > 1000 atrial ectopic beats, n (%) | 5 (16) |
| Supraventricular runs, ≥ 5 beats, n (%) | 9 (29) |
| Atrial fibrillation, n (%) | 1 (3) |
| Ventricular ectopic beats, n (%) | 17 (54.84) |
| Ventricular ectopic beats, mean (s.d.) | 197 (527) |
| > 1000 ventricular ectopic beats | 2 (6.5) |
| Ventricular couplets, n (%) | 5 (16) |
| Ventricular triplet, n (%) | 1 (3) |
| Ventricular bigeminy, n (%) | 6 (19.35) |
| Ventricular trigeminy, n (%) | 3 (9.68) |
| Non-sustained ventricular tachycardia, n (%) | 1 (3) |
| Sustained ventricular tachycardia, n (%) | 0 (0) |

aAny interstitial lung disease detected on high-resolution CT. BNP: B-type natriuretic peptide; FVC: forced vital capacity; IQR: interquartile range; mRSS: modified Rodnan skin score; Scl-70: anti-topoisomerase.
There is significant interest in the early detection of SHI during an active, potentially reversible phase of myocardial disease as a strategy to improve patient outcomes. However, our results suggest that, at least in the early stages of SSc, structural heart disease and electrophysiological abnormalities do not develop or progress in parallel and that a complete cardiac evaluation requires both structural and functional studies as well as interrogation for any electrophysiological changes. Whether reversal of structural heart muscle changes can limit the development of future arrhythmias or reduce the risk of sudden cardiac death remains unknown.

A limitation of this study was the lack of ECG control data. VEs are a common finding in the general population and a higher burden of VEs has been associated with poorer cardiac outcomes and increased mortality [17]. While we acknowledge that this study may have been underpowered to detect an association between myocardial fibrosis and arrhythmia, this study serves as an important counterbalance to studies of similar size that have proposed positive associations despite the risk of Type I error. The lack of association, even though myocardial fibrosis and arrhythmias were relatively common in this study, suggests that caution is required in basing clinical decisions on these non-invasive surrogates. It is possible that with more extended monitoring a higher frequency of arrhythmic events would have been recorded. The yield of prolonged ECG monitoring in SSc is unknown. More prolonged monitoring usually necessitates the implantation of a monitoring device, the indications for which are ill-defined in SSc, particularly given concerns about wound healing in patients with significant cutaneous chest wall involvement and infection risk for immunosuppressed patients.

It is possible that the clinical significance of myocardial fibrosis in SSc only becomes apparent over time and this study was limited by a lack of clinical follow-up, meaning our results may underestimate the relationship between myocardial fibrosis and arrhythmia. We did not have any histopathological validation of the CMR findings; however, it would have been unethical to include biopsy as part of this study given the invasive nature of the procedure and its inherent risks. We have demonstrated that diffuse myocardial fibrosis is a near-universal finding among SSc patients without cardiac symptoms or history of SHI, regardless of disease duration or extent of skin involvement, and that it can be considered a hallmark of the disease. CMR has an emerging role in the diagnosis of SHI, however its prognostic utility remains unproven. We observed a high prevalence of important abnormalities using electrocardiography and CMR, however we found no clear association between cardiac arrhythmias and the extent of myocardial fibrosis in patients without clinical symptoms of cardiac disease. We reinforce evidence that SSc patients are at increased risk of cardiac complications but simultaneously temper enthusiasm for the use of non-invasive markers of myocardial fibrosis in assessing risk of significant ventricular arrhythmia in the absence of cardiac symptoms and in those patients without clinical suspicion of SHI.

**Funding:** This work was supported by a National Heart Foundation of Australia Vanguard Grant [102206], Arthritis Australia—Australian Rheumatology Association Project Grant, Scleroderma Victoria Project Grant, St Vincent’s Hospital Research Endowment Fund Project Grant [88371], The University of Melbourne Research Establishment Grant, MSK Australia PhD Scholarship and an Australian Government Research Training Program Scholarship to L.R., the University of Melbourne Research Training Scholarship to Z.B., National Health and Medical Research Council of Australia Investigator Grant [GNT 1176538] to M.N. and the Australian National Heart Foundation Future Leader Fellowship [102021] to A.L.G.

**TABLE 2** Comparison of CMR parameters and electrocardiography abnormalities

|                | Ventricular ectopic beats | Atrial ectopic beats |
|----------------|--------------------------|----------------------|
|                | Coef.                   | P-value (95% CI)     | R²      | Coef.       | P-value (95% CI) | R²      |
| Native T1-time (SASHA) | 0.38                     | 0.858                | 0.001   | 3.23        | 0.898           | <0.001 |
| Native T1-time (ShMOLLI) | 3.83                     | 0.125                | 0.079   | 53.96       | 0.063           | 0.114  |
| Native T2-time | -45.80                   | 0.074                | 0.106   | -200.79     | 0.515           | 0.015  |
| LGE            | 124.59                   | 0.568                | 0.012   | 3461.83     | 0.171           | 0.066  |

CMR: cardiac magnetic resonance imaging; ECV: extra-cellular volume; LGE: late gadolinium enhancement; SASHA: saturated recovery single-shot acquisition; ShMOLLI: shortened Modified look locker sequence.
Disclosure statement: M.N. receives research support from Actelion, AstraZeneca, Bristol Myers Squibb, GlaxoSmithKline, Janssen and UCB. M.N. has received honoraria from Actelion, Boehringer Ingelheim, Eli Lilly, GlaxoSmithKline, Janssen, Pfizer and UCB. All other authors have no conflicts of interest to disclose. Data availability statement: The data underlying this article will be shared on reasonable request to the corresponding author.

Data availability statement
The data underlying this article cannot be shared publicly due for the privacy of the individuals that participated in the study. The data will be shared on reasonable request to the corresponding author.

Supplementary data
Supplementary data are available at Rheumatology online.

References
1 Tyndall AJ, Bannert B, Vonk M et al. Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Ann Rheum Dis 2010;69:1809–15.
2 Bulkley BH, Ridolfi RL, Salyer WR, Hutchins GM. Myocardial lesions of progressive systemic sclerosis: a cause of cardiac dysfunction. Circulation 1976;53:483–90.
3 Krumm P, Mueller KA, Klingel K et al. Cardiovascular magnetic resonance patterns of biopsy proven cardiac involvement in systemic sclerosis. J Cardiovasc Magn Reson 2016;18:70.
4 Vacc a A, Meune C, Gordon J et al. Cardiac arrhythmias and conduction system involvement in systemic sclerosis. Rheumatology (Oxford) 2014;53:1172–7.
5 Haaf P, Garg P, Messroghli DR et al. Cardiac T1-mapping and extracellular volume (ECV) in clinical practice: a comprehensive review. J Cardiovasc Magn Reson 2016;18:89.
6 van den Hoogen F, Khanna D, Fransen J et al. 2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis 2013;72:1747–55.
7 LeRoy EC, Black C, Fleischmajer R et al. Scleroderma (systemic sclerosis): classification, subsets & pathogenesis. J Rheumatol 1988;15:202–5.
8 Costello BT, Springer F, Hare JL et al. SASHA versus SHMOLLI: a comparison of T1 mapping methods in health and dilated cardiomyopathy at 3 T. Int J Cardiovasc Imaging 2017;33:1551–60.
9 Ntusi N, Piechnik S, Francis JM et al. Subclinical myocardial inflammation and diffuse fibrosis are common in systemic sclerosis – a clinical study using myocardial T1-mapping and extracellular volume quantification. J Cardiovasc Magn Reson 2014;16:1–12.
10 Poindron V, Chatelus E, Canuet M et al. T1 mapping cardiac magnetic resonance imaging frequently detects subclinical diffuse myocardial fibrosis in systemic sclerosis patients. Semin Arthritis Rheum 2020;50:128–34.
11 Barison A, Gargani L, De Marchi D et al. Early myocardial and skeletal muscle interstitial remodelling in systemic sclerosis: insights from extracellular volume quantification using cardiovascular magnetic resonance. Eur Heart J Cardiovasc Imaging 2015;16:74–80.
12 Hromádk a M, Seidlerová J, Suchý D et al. Myocardial fibrosis detected by magnetic resonance in systemic sclerosis patients – Relationship with biochemical and echocardiography parameters. Int J Cardiol 2017;249:448–53.
13 Markouzis-Mavrogenis G, Bournia VK, Panopoulos S et al. Cardiovascular magnetic resonance identifies high-risk systemic sclerosis patients with normal echocardiograms and provides incremental prognostic value. Diagnostics (Basel) 2019;9:220.
14 Markouzis-Mavrogenis G, Koutsogeorgopoulou L, Katsifis G et al. The doubled-edged sword of T1-mapping in systemic sclerosis—a comparison with infectious myocarditis using cardiovascular magnetic resonance. Diagnostics (Basel) 2020;10:335.
15 Terrier B, Dechartres A, Gouya H et al. Cardiac intravoxel incoherent motion diffusion-weighted magnetic resonance imaging with T1 mapping to assess myocardial perfusion and fibrosis in systemic sclerosis: association with cardiac events from a prospective cohort study. Arthritis Rheum 2020;72:1571–80.
16 Zhuang B, Sirajuddin A, Wang S et al. Prognostic value of T1 mapping and extracellular volume fraction in cardiovascular disease: a systematic review and meta-analysis. Heart Fail Rev 2018;23:723–31.
17 Gorenek B, Fisher JD, Kudaiberdieva G et al. Premature ventricular complexes: diagnostic and therapeutic considerations in clinical practice: a state-of-the-art review by the American College of Cardiology Electrophysiology Council. J Interv Card Electrophysiol 2020;57:5–26.
18 Mavrogeni S, Gargani L, Pepe A et al. Cardiac magnetic resonance predicts ventricular arrhythmias in scleroderma: the Scleroderma Arrhythmia Clinical Utility Study (SAnCtUS). Rheumatology (Oxford) 2020;59:1938–48.
19 Allanore Y, Meune C. Primary myocardial involvement in systemic sclerosis: evidence for a microvascular origin. Clin Exp Rheumatol 2010;28:548–53.
20 Bissell LA, Dumitru RB, Erhayemi B et al. Incidental significant arrhythmia in scleroderma associates with cardiac magnetic resonance measure of fibrosis and hs-TnI and NT-proBNP. Rheumatology (Oxford) 2019;58:1221–6.